Patents by Inventor Elinborg Ostermann
Elinborg Ostermann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210230271Abstract: Chimeric and humanized anti-CD37 antibodies and pharmaceutical compositions containing them are useful for the treatment of B cell malignancies and autoimmune and inflammatory diseases that involve B cells in their pathology.Type: ApplicationFiled: November 4, 2020Publication date: July 29, 2021Inventors: Karl-Heinz HEIDER, Eric BORGES, Elinborg OSTERMANN
-
Publication number: 20180186876Abstract: Chimeric and humanized anti-CD37 antibodies and pharmaceutical compositions containing them are useful for the treatment of B cell malignancies and autoimmune and inflammatory diseases that involve B cells in their pathology.Type: ApplicationFiled: February 15, 2018Publication date: July 5, 2018Inventors: Karl-Heinz HEIDER, Eric BORGES, Elinborg OSTERMANN
-
Patent number: 9932399Abstract: Chimeric and humanized anti-CD37 antibodies and pharmaceutical compositions containing them are useful for the treatment of B cell malignancies and autoimmune and inflammatory diseases that involve B cells in their pathology.Type: GrantFiled: April 22, 2015Date of Patent: April 3, 2018Assignee: Boehringer Ingelheim International GmbHInventors: Karl-Heinz Heider, Eric Borges, Elinborg Ostermann
-
Publication number: 20160137729Abstract: Chimeric and humanized anti-CD37 antibodies and pharmaceutical compositions containing them are useful for the treatment of B cell malignancies and autoimmune and inflammatory diseases that involve B cells in their pathology.Type: ApplicationFiled: April 22, 2015Publication date: May 19, 2016Inventors: Karl-Heinz HEIDER, Eric BORGES, Elinborg OSTERMANN
-
Patent number: 9078879Abstract: Chimeric and humanized anti-CD37 antibodies and pharmaceutical compositions containing them are useful for the treatment of B cell malignancies and autoimmune and inflammatory diseases that involve B cells in their pathology.Type: GrantFiled: August 23, 2013Date of Patent: July 14, 2015Assignee: Boehringer Ingelheim International GmbHInventors: Karl-Heinz Heider, Eric Borges, Elinborg Ostermann
-
Publication number: 20140010808Abstract: Chimeric and humanized anti-CD37 antibodies and pharmaceutical compositions containing them are useful for the treatment of B cell malignancies and autoimmune and inflammatory diseases that involve B cells in their pathology.Type: ApplicationFiled: August 23, 2013Publication date: January 9, 2014Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Karl-Heinz HEIDER, Eric BORGES, Elinborg OSTERMANN
-
Publication number: 20140004110Abstract: Chimeric and humanized anti-CD37 antibodies and pharmaceutical compositions containing them are useful for the treatment of B cell malignancies and autoimmune and inflammatory diseases that involve B cells in their pathology.Type: ApplicationFiled: August 23, 2013Publication date: January 2, 2014Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Karl-Heinz HEIDER, Eric BORGES, Elinborg OSTERMANN
-
Patent number: 8580254Abstract: Antibody molecules, in particular fully human antibodies that bind to human IGF-1 and cross-react with IGF-2 such that binding of IGF-1 and IGF-2 to the IGF-1 receptor is prevented and IGF-1 receptor-mediated signaling is inhibited. The antibodies do not bind to insulin and thus do not affect the mitogenic properties of insulin that are mediated by its binding to the insulin receptors. The antibodies are useful for the treatment of hyperproliferative diseases, in particular cancer.Type: GrantFiled: June 19, 2008Date of Patent: November 12, 2013Assignee: Boehringer Ingelheim International GmbHInventors: Paul Adam, Elinborg Ostermann
-
Patent number: 8568727Abstract: Anti-FAP-antibodies and immunoconjugates, pharmaceutical compositions containing such conjugates, and their use in cancer therapy.Type: GrantFiled: December 22, 2006Date of Patent: October 29, 2013Assignee: Boehringer Ingelheim International GmbHInventors: Guenther Adolf, Elinborg Ostermann, Milena Kalat, Karl-Heinz Heider
-
Publication number: 20110165153Abstract: Chimeric and humanized anti-CD37 antibodies and pharmaceutical compositions containing them are useful for the treatment of B cell malignancies and autoimmune and inflammatory diseases that involve B cells in their pathology.Type: ApplicationFiled: September 17, 2010Publication date: July 7, 2011Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Karl-Heinz HEIDER, Eric BORGES, Elinborg OSTERMANN
-
Publication number: 20100196395Abstract: Antibody molecules, in particular fully human antibodies that bind to human IGF-1 and cross-react with IGF-2 such that binding of IGF-1 and IGF-2 to the IGF-1 receptor is prevented and IGF-1 receptor-mediated signaling is inhibited. The antibodies do not bind to insulin and thus do not affect the mitogenic properties of insulin that are mediated by its binding to the insulin receptors. The antibodies are useful for the treatment of hyperproliferative diseases, in particular cancer.Type: ApplicationFiled: June 19, 2008Publication date: August 5, 2010Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Paul Adam, Elinborg Ostermann
-
Publication number: 20100189722Abstract: Chimeric and humanized anti-CD37 antibodies and pharmaceutical compositions containing them are useful for the treatment of B cell malignancies and autoimmune and inflammatory diseases that involve B cells in their pathology.Type: ApplicationFiled: August 8, 2008Publication date: July 29, 2010Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Karl-Heinz Heider, Eric Borges, Elinborg Ostermann
-
Publication number: 20090304718Abstract: Anti-FAP-antibodies and immunoconjugates, pharmaceutical compositions containing such conjugates, and their use in cancer therapy.Type: ApplicationFiled: December 22, 2006Publication date: December 10, 2009Inventors: Guenther Adolf, Elinborg Ostermann, Milena Kalat, Karl-Heinz Heider
-
Patent number: 7417127Abstract: The present invention belongs to the field of oncology. The invention relates to antibodies with specified sequence which are specific for an epitope which is coded by the variant exon v6 of the CD44 gene and to derivatives of said antibody. The invention also provides nucleic acid molecules encoding said antibody proteins. The invention furthermore pertains to methods for producing said antibody proteins. The invention also provides pharmaceutical compositions comprising said antibody proteins. The invention furthermore is concerned with the use in the manufacture of a medicament for the treatment of cancer.Type: GrantFiled: May 25, 2005Date of Patent: August 26, 2008Assignees: Boehringer Ingelheim Pharmaceuticals, Inc., Bohringer Ingelheim International GmbHInventors: Gunther Adolf, Elinborg Ostermann, Erik Patzelt, Marlies Sproll, Karl-Heinz Heider, John J. Miglietta, Augustinus Antonius Maria Silvester Van Dongen
-
Patent number: 6972324Abstract: The present invention belongs to the field of oncology. The invention relates to antibodies with specified sequence which are specific for an epitope which is coded by the variant exon v6 of the CD44 gene and to derivatives of said antibody. The invention also provides nucleic acid molecules encoding said antibody proteins. The invention furthermore pertains to methods for producing said antibody proteins. The invention also provides pharmaceutical compositions comprising said antibody proteins. The invention furthermore is concerned with the use in the manufacture of a medicament for the treatment of cancer.Type: GrantFiled: May 20, 2002Date of Patent: December 6, 2005Assignees: Boehringer Ingelheim Pharmaceuticals, Inc., Boehringer Ingelheim International, GmbHInventors: Günther Adolf, Elinborg Ostermann, Erik Patzelt, Marlies Sproll, Karl-Heinz Heider, John J. Miglietta, Augustinus Antonius Maria Silvester Van Dongen
-
Publication number: 20050214212Abstract: The present invention belongs to the field of oncology. The invention relates to antibodies with specified sequence which are specific for an epitope which is coded by the variant exon v6 of the CD44 gene and to derivatives of said antibody. The invention also provides nucleic acid molecules encoding said antibody proteins. The invention furthermore pertains to methods for producing said antibody proteins. The invention also provides pharmaceutical compositions comprising said antibody proteins. The invention furthermore is concerned with the use in the manufacture of a medicament for the treatment of cancer.Type: ApplicationFiled: May 25, 2005Publication date: September 29, 2005Inventors: Gunther Adolf, Elinborg Ostermann, Erik Patzelt, Marlies Sproll, Karl-Heinz Heider, John Miglietta, Augustinus Antonius Van Dongen
-
Patent number: 6759211Abstract: The present invention is generally directed to the identification of mouse and human genes that inhibit the growth of a tumor and induce apoptosis in cancer cells, and to polypeptides encoded by such genes. In particular, the invention concerns the nucleotide sequence of one such tumor-inhibiting gene, tag7, and the amino acid sequence of a polypeptide encoded by tag7. The invention also provides isolated nucleic acid molecules comprising tag7 polynucleotides, and vectors and host cells comprising these isolated nucleic acid molecules. The invention also provides methods of producing tag7 polynucleotides using these nucleic acid molecules, vectors and host cells, tag7 polypeptides made by three methods and antibodies that specifically bind to the tag7 polypeptide. The invention also concerns methods of inhibiting tumor growth and inducing tumor cell apoptosis, and methods of cancer therapy, using the present tag7 nucleic acid molecules and polypeptides.Type: GrantFiled: July 28, 2000Date of Patent: July 6, 2004Assignee: Boehringer Ingelheim International GmbHInventors: Georgii Georgiev, Sergei Kiselev, Egor Prokhorchouk, Elinborg Ostermann
-
Publication number: 20030190319Abstract: The present invention belongs to the field of oncology. The invention relates to antibodies with specified sequence which are specific for an epitope which is coded by the variant exon v6 of the CD44 gene and to derivatives of said antibody. The invention also provides nucleic acid molecules encoding said antibody proteins. The invention furthermore pertains to methods for producing said antibody proteins. The invention also provides pharmaceutical compositions comprising said antibody proteins. The invention furthermore is concerned with the use in the manufacture of a medicament for the treatment of cancer.Type: ApplicationFiled: May 20, 2002Publication date: October 9, 2003Inventors: Gunther Adolf, Elinborg Ostermann, Erik Patzelt, Marlies Sproll, Karl-Heinz Heider, John J. Miglietta, Augustinus Antonius Maria Silvester Van Dongen
-
Publication number: 20020137670Abstract: Complex of DNA, containing one or more DNA molecules coding for one or more therapeutically active proteins with a cytotoxic activity, and a polycation conjugated with transferrin with a zeta potential of ≦+15 mV. The complex, in which a high transferrin content screens the positive charge, produces a targeted transportation of the therapeutic DNA to the tumors in the systemic treatment of tumor diseases.Type: ApplicationFiled: October 3, 2001Publication date: September 26, 2002Applicant: Boehringer Ingelheim International GmbH.Inventors: Ralf Kircheis, Ernst Wagner, Lionel Wightman, Elinborg Ostermann
-
Patent number: 6172211Abstract: The present invention is generally directed to the identification of mouse and human genes that inhibit the growth of a tumor and induce apoptosis in cancer cells, and to polypeptides encoded by such genes. In particular, the invention concerns the nucleotide sequence of one such tumor-inhibiting gene, tag7, and the amino acid sequence of a polypeptide encoded by tag7. The invention also provides isolated nucleic acid molecules comprising tag7 polynucleotides, and vectors and host cells comprising these isolated nucleic acid molecules. The invention also provides methods of producing tag7 polypeptides using these nucleic acid molecules, vectors and host cells, tag7 polypeptides made by these methods and antibodies that specifically bind to the tag7 polypeptide. The invention also concerns methods of inhibiting tumor growth and inducing tumor cell apoptosis, and methods of cancer therapy, using the present tag7 nucleic acid molecules and polypeptides.Type: GrantFiled: July 11, 1997Date of Patent: January 9, 2001Assignee: Boehringer Ingelheim International GmbHInventors: Georgii P. Georgiev, Sergei L. Kiselev, Egor B. Prokhorchouk, Elinborg Ostermann